# Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension

Study · id `cardio:ct-nct03945305` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03945305](<https://clinicaltrials.gov/study/NCT03945305>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03945305

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.

## Technical summary

Registry record NCT03945305. Randomized; single masking; primary purpose treatment. Start 2023-11-25 (actual); primary completion 2026-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT03945305, source copy `cardio:ctgov-nct03945305-2026-07-28`, retrieved 2026-10-26)
- Started: 2023-11-25 (actual) (ClinicalTrials.gov record NCT03945305, source copy `cardio:ctgov-nct03945305-2026-07-28`, retrieved 2026-10-26)
- Primary completion: 2026-07-31 (anticipated) (ClinicalTrials.gov record NCT03945305, source copy `cardio:ctgov-nct03945305-2026-07-28`, retrieved 2026-10-26)
- Completion: 2026-07-31 (anticipated) (ClinicalTrials.gov record NCT03945305, source copy `cardio:ctgov-nct03945305-2026-07-28`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03945305, source copy `cardio:ctgov-nct03945305-2026-07-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03945305-2026-07-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Device): Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning.
- Intervention (Other): Previous antihypertensive treatment
- Lead sponsor: Yi Yang
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Yi Yang (`cardio:org-yi-yang`)

## Provenance

Content hash: 684bf73977d2b39ad9b0ee83c54cbf34a5f81d62172f2d32526326ff62d10bcd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
